External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>AIL reported revenue growth of 8.3% YoY in Q3FY24 (versus our expectations of 8% YoY), slightly in line with IPM's 9.8% growth.</li><li>A change in product mix, and a higher share of the antidiabetics, vitamins, and Hormones which reported YoY growth of 11.2%, 10.8% and 16.4% respectively, resulted in higher sales growth.</li><li>However, this was partially offset by Mixtard and Novomix, which recorded -0.4% growth and -11.8% YoY de-growth, leading to high single-digit topline growth to some extent.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

AIL reported revenue growth of 8.3% YoY in Q3FY24 (versus our expectations of 8% YoY), slightly in line with IPM's 9.8% growth.A change in product mix, and a higher share of the antidiabetics, vitamins, and Hormones which reported YoY growth of 11.2%, 10.8% and 16.4% respectively, resulted in higher sales growth.However, this was partially offset by Mixtard and Novomix, which recorded -0.4% growth and -11.8% YoY de-growth, leading to high single-digit topline growth to some extent.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India Ltd - Highest Ever EBITDA Margins

ABB India Ltd

Abbott India Ltd - Highest Ever EBITDA Margins